IN2014MN02082A - - Google Patents
Info
- Publication number
- IN2014MN02082A IN2014MN02082A IN2082MUN2014A IN2014MN02082A IN 2014MN02082 A IN2014MN02082 A IN 2014MN02082A IN 2082MUN2014 A IN2082MUN2014 A IN 2082MUN2014A IN 2014MN02082 A IN2014MN02082 A IN 2014MN02082A
- Authority
- IN
- India
- Prior art keywords
- formula
- disclosed
- methods
- administering
- treating
- Prior art date
Links
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 102000000551 Syk Kinase Human genes 0.000 abstract 1
- 108010016672 Syk Kinase Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/305—Mercury compounds
- A61K31/31—Mercury compounds containing nitrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261614274P | 2012-03-22 | 2012-03-22 | |
| PCT/US2013/032575 WO2013142382A1 (en) | 2012-03-22 | 2013-03-15 | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014MN02082A true IN2014MN02082A (instruction) | 2015-08-21 |
Family
ID=49223277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2082MUN2014 IN2014MN02082A (instruction) | 2012-03-22 | 2013-03-15 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8877763B2 (instruction) |
| EP (1) | EP2828259B1 (instruction) |
| JP (1) | JP6101341B2 (instruction) |
| KR (1) | KR102011770B1 (instruction) |
| CN (1) | CN104428298B (instruction) |
| AU (1) | AU2013235344B2 (instruction) |
| BR (1) | BR112014023460B1 (instruction) |
| CA (1) | CA2868156C (instruction) |
| CL (1) | CL2014002505A1 (instruction) |
| EA (1) | EA031267B1 (instruction) |
| ES (1) | ES2694223T3 (instruction) |
| IL (1) | IL234802B (instruction) |
| IN (1) | IN2014MN02082A (instruction) |
| MX (1) | MX360912B (instruction) |
| MY (1) | MY184858A (instruction) |
| NZ (1) | NZ700283A (instruction) |
| PL (1) | PL2828259T3 (instruction) |
| SG (1) | SG11201405942RA (instruction) |
| TR (1) | TR201816480T4 (instruction) |
| WO (1) | WO2013142382A1 (instruction) |
| ZA (1) | ZA201407588B (instruction) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014340249B2 (en) * | 2013-10-21 | 2017-05-25 | Genosco | Substituted pyrimidine compounds and their use as SYK inhibitors |
| AU2015291522B2 (en) * | 2014-07-17 | 2018-12-06 | Sunshine Lake Pharma Co., Ltd. | Substituted urea derivatives and pharmaceutical uses thereof |
| KR20160035411A (ko) * | 2014-09-23 | 2016-03-31 | 주식회사 오스코텍 | LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물 |
| EP3804725A3 (en) | 2014-11-17 | 2021-07-07 | Rhode Island Hospital | Nanomaterial compositions, synthesis, and assembly |
| US12350272B2 (en) * | 2018-06-27 | 2025-07-08 | Oscotec Inc. | Pyridopyrimidinone derivatives for use as AXL inhibitors |
| KR20200022712A (ko) * | 2018-08-23 | 2020-03-04 | 주식회사 오스코텍 | 8-브로모-2-(1-메틸피페리딘-4-일아미노)-4-(4-페녹시페닐아미노)피리도[4,3-d]피리미딘-5(6H)-온 염산염의 결정다형체 및 그 제조방법 |
| KR102230721B1 (ko) | 2019-02-01 | 2021-03-22 | 주식회사 오스코텍 | 피리도피리미딘계 염산염을 포함하는 경구용 고형제제 및 이의 제조방법 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| CN110327347B (zh) * | 2019-08-16 | 2021-06-01 | 陕西科技大学 | G-749在制备抗真菌药物中的应用 |
| TWI759829B (zh) | 2019-08-23 | 2022-04-01 | 財團法人生物技術開發中心 | 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物 |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| WO2023027966A1 (en) | 2021-08-24 | 2023-03-02 | Biomea Fusion, Inc. | Pyrazine compounds as irreversible inhibitors of flt3 |
| IL313670A (en) | 2021-12-30 | 2024-08-01 | Biomea Fusion Inc | Pyrazine compounds as inhibitors of FLT3 |
| WO2023225005A1 (en) | 2022-05-17 | 2023-11-23 | Biomea Fusion, Inc. | Flt3 combination therapy for cancer and compositions therefor |
| KR102440707B1 (ko) | 2022-07-10 | 2022-09-05 | 이우미 | 공장 추천 시스템 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL357634A1 (en) * | 2000-01-27 | 2004-07-26 | Warner-Lambert Company | Pyridopyrimidinone derivatives for treatment of neurodegenerative disease |
| WO2002018379A2 (en) * | 2000-08-31 | 2002-03-07 | F. Hoffmann-La Roche Ag | 7-oxo pyridopyrimidines |
| JP4141830B2 (ja) * | 2000-08-31 | 2008-08-27 | エフ．ホフマン−ラ ロシュ アーゲー | 細胞増殖の阻害剤としての７−オキソ−ピリドピリミジン類 |
| EP2025678A1 (en) * | 2007-08-17 | 2009-02-18 | Oncalis AG | Pyrazolo[3,4-d]pyrimidine compounds and their use as modulators of protein kinase |
| TW200942537A (en) * | 2008-02-01 | 2009-10-16 | Irm Llc | Compounds and compositions as kinase inhibitors |
| EP2330909B1 (en) * | 2008-08-12 | 2013-09-18 | GlaxoSmithKline LLC | Chemical compounds |
| US8338481B2 (en) * | 2009-01-28 | 2012-12-25 | Ramot At Tel-Aviv University Ltd. | Alkoxyalkyl S-prenylthiosalicylates for treatment of cancer |
| CN102470127A (zh) * | 2009-08-19 | 2012-05-23 | 埃姆比特生物科学公司 | 联芳基化合物和其使用方法 |
| ES2658290T3 (es) | 2009-10-29 | 2018-03-09 | Genosco | Inhibidores de cinasa |
-
2013
- 2013-03-15 US US13/841,827 patent/US8877763B2/en active Active
- 2013-03-15 MY MYPI2014702705A patent/MY184858A/en unknown
- 2013-03-15 CA CA2868156A patent/CA2868156C/en active Active
- 2013-03-15 KR KR1020147029509A patent/KR102011770B1/ko active Active
- 2013-03-15 TR TR2018/16480T patent/TR201816480T4/tr unknown
- 2013-03-15 AU AU2013235344A patent/AU2013235344B2/en active Active
- 2013-03-15 WO PCT/US2013/032575 patent/WO2013142382A1/en not_active Ceased
- 2013-03-15 IN IN2082MUN2014 patent/IN2014MN02082A/en unknown
- 2013-03-15 PL PL13763998T patent/PL2828259T3/pl unknown
- 2013-03-15 MX MX2014011354A patent/MX360912B/es active IP Right Grant
- 2013-03-15 EA EA201491747A patent/EA031267B1/ru not_active IP Right Cessation
- 2013-03-15 NZ NZ700283A patent/NZ700283A/en unknown
- 2013-03-15 SG SG11201405942RA patent/SG11201405942RA/en unknown
- 2013-03-15 EP EP13763998.5A patent/EP2828259B1/en active Active
- 2013-03-15 ES ES13763998.5T patent/ES2694223T3/es active Active
- 2013-03-15 BR BR112014023460-4A patent/BR112014023460B1/pt active IP Right Grant
- 2013-03-15 JP JP2015501823A patent/JP6101341B2/ja active Active
- 2013-03-15 CN CN201380025782.8A patent/CN104428298B/zh active Active
-
2014
- 2014-09-22 CL CL2014002505A patent/CL2014002505A1/es unknown
- 2014-09-22 IL IL234802A patent/IL234802B/en active IP Right Grant
- 2014-10-20 ZA ZA2014/07588A patent/ZA201407588B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2014002505A1 (es) | 2015-10-02 |
| MY184858A (en) | 2021-04-27 |
| CN104428298B (zh) | 2017-03-01 |
| JP2015510942A (ja) | 2015-04-13 |
| CN104428298A (zh) | 2015-03-18 |
| ES2694223T3 (es) | 2018-12-19 |
| HK1208453A1 (en) | 2016-03-04 |
| MX360912B (es) | 2018-11-22 |
| IL234802B (en) | 2018-10-31 |
| CA2868156C (en) | 2020-07-28 |
| EP2828259A1 (en) | 2015-01-28 |
| AU2013235344A1 (en) | 2014-10-09 |
| KR102011770B1 (ko) | 2019-08-19 |
| BR112014023460B1 (pt) | 2020-09-01 |
| US20130274274A1 (en) | 2013-10-17 |
| EA201491747A1 (ru) | 2015-10-30 |
| KR20140144709A (ko) | 2014-12-19 |
| EP2828259B1 (en) | 2018-08-08 |
| SG11201405942RA (en) | 2014-10-30 |
| AU2013235344B2 (en) | 2017-03-16 |
| WO2013142382A1 (en) | 2013-09-26 |
| EA031267B1 (ru) | 2018-12-28 |
| MX2014011354A (es) | 2014-12-05 |
| TR201816480T4 (tr) | 2018-11-21 |
| CA2868156A1 (en) | 2013-09-26 |
| EP2828259A4 (en) | 2015-08-19 |
| NZ700283A (en) | 2016-08-26 |
| JP6101341B2 (ja) | 2017-03-22 |
| PL2828259T3 (pl) | 2019-02-28 |
| US8877763B2 (en) | 2014-11-04 |
| ZA201407588B (en) | 2015-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014MN02082A (instruction) | ||
| PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
| PH12018500041A1 (en) | Substituted aza compoounds as irak-4 inhibitors | |
| PH12014502757B1 (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| MY178621A (en) | Deuterated cftr potentiators | |
| TN2013000348A1 (en) | Compounds and compositions as trk inhibitors | |
| HK1203927A1 (en) | Heterocyclic compounds and uses as anticancer agents | |
| NZ700928A (en) | Dna-pk inhibitors | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| EA023222B8 (ru) | Пиразолилхиноксалиновые ингибиторы киназы | |
| WO2013134336A3 (en) | Inhibition of adaptor associated kinase 1 for the treatment of pain | |
| MX2013010016A (es) | Compuestos de quinazolina sustituidos con alquino y metodos uso. | |
| IN2015DN01156A (instruction) | ||
| NZ630925A (en) | Pyrazolopyrimidine compounds as kinase inhibitors | |
| MX2020004183A (es) | Compuestos aromaticos multisustituidos como inhibidores de serina proteasa. | |
| MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
| WO2014031438A3 (en) | SUBSTITUTED PHENYL SPLEEN TYROSINE KINASE (Syk) INHIBITORS | |
| SG10201805392YA (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| IN2015MN00002A (instruction) | ||
| PH12016500735B1 (en) | Substituted pyrimidine compounds and their use as syk inhibitors | |
| IN2014DN07224A (instruction) | ||
| EA201590744A1 (ru) | Лечение рака tor киназными ингибиторами | |
| IN2014DN07954A (instruction) | ||
| IN2014DN07220A (instruction) | ||
| WO2014160177A3 (en) | Quinazoline inhibitors of pi3k |